View
126
Download
13
Category
Preview:
Citation preview
1
INFECTII CUTANATEVIRALE
2
Conflict de interese
• Astellas Pharma• Glaxo SmithKline• Hoffman LaRoche• Janssen Pharma• Schering AG• Schering Plough• L’Oreal
• Sir Samuel Scott ofYews Trust
• European DermatoEpidemiologyNetwork
• Archives ofDermatology
3
Foarte variateDepind de:
Tipul virusuluiLocalizarea infectieiRaspunsul imun al gazdei
Unele virusuri pot doar coloniza epidermul, fara aproduce manifestari clinice (ex: HPV, v.molluscumului contagiosum)
Manifestari clinice
4
Virusuri care produc infectiicutanate (I)
Papilomavirusuri umaneVirusuri herpetice
Virusul herpes simplex 1, 2Virusul varicelo-zosterianVirusul Epstein-BarrHerpesvirusul uman 6, 7, 8
Pox-virusuriVirusul molluscumului contagiosumVirusul nodulilor mulgatorilorVirusul ectimei contagiosum (orf)
5
Virusuri care produc infectiicutanate (II)
Virusurile bolilor eruptive ale copilariei(rujeola, rubeola, varicela)Virusul hepatitei B (vasculite, urticariecronica)
6
Despre ce voi vorbi...
• Papilomavirusuri umane• Herpes simplex• Herpes zoster• Poxvirusuri• Pitiriazis rozat• Sarcom Kaposi• Manifestari cutanate in infectia HIV
7
Papilomavirusuri umane
Caractere generaleGrup de >100 virusuri ADNProduc proliferarea epiteliilor pielii simucoaselorDetermina de obicei leziuni benigneUnele tipuri pot produce leziuni displazicesau neoplazice
8
Papilomavirusuri umanemanifestari clinice (I)
Veruci vulgareVeruci plantare
ProfundeSuperficiale (in mozaic)
Veruci plane (juvenile)Papiloame (veruci filiforme/digitate)
9
Papilomavirusuri umanemanifestari clinice (II)
Condiloame (veruci) anogenitaleCondiloame acuminateCondiloame plane ale colului uterinCondilomatoza giganta
Papuloza bowenoidaEpidermodisplazia veruciforma
10
11
12
13
14
15
16
17
18
19
20
Papilomavirusuri umane tratament
Acid salicilic 15-25%Acid mono-, tricloracetic 25-30%Podofilina 25%/podofilotoxina 0,5%CrioterapieSensibilizanti de contact (DNCB, DCP)Citostatice topice/intralezionaleMetode chirurgicale: curetaj,electrocoagulare, laser CO2
21
Papilomavirusuriinfectii genitale (I)
Cea mai frecventa ITSIncidenta in crestere: ↑25% barbati,↑28% femei - 1999 vs. 199390% din condiloame sunt produse detipuri neoncogene (PVU 6, 11)Majoritatea celor infectati nu aucondiloame vizibile (posibil doar 1%dintre cei infectati)
22
Papilomavirusuriinfectii genitale
Cu risc oncogen mare (16, 18)Majoritatea cazurilor de carcinom de col uterin secoreleaza cu PVU 16, 18; frecvent produc infectiiasimptomatice
Cu risc oncogen mic (6, 11)Produc un carcinom spinocelular neagresiv (Buschke-Loewenstein)
Sunt posibile coinfectii cu mai multe tipuri
23
24
25
26
Papilomavirusuriinfectii genitale
Testarea ADN-ului pentru tipurilorcu risc mare:
Utilitatea testarii depinde de Sb, Sp siprevalenta infectiei cu risc mareCel mai utilizat test (Digene) are Sb90%, Sp 15-20% → rata mare defals+testul este autorizat de FDA pentruprobe recoltate din colul uterin
27
Papilomavirusuri - infectii genitaleepidemiologie
Transmiterea este facilitata de existentaleziunilor (dar nu exclusiva)Transmiterea mediata de obiecte esteposibila, dar nedoveditaTransmiterea cu ocazia nasterii este rara(papiloame laringiene sau condiloameanogenitale la luni de zile post-partum)Infectivitatea inter-parteneri: 60%Utilizarea prezervativului reducetransmiterea
28
Papilomavirusuri - infectii genitalefactori de risc
Numarul partenerilor sexualiFrecventa contactelor sexualePrezenta condiloamelor la partenerFumatul (factor de risc independent)
29
Condiloame acuminatediagnostic
Clinicutilizarea acidului acetic (aceto-whitening) nerecomandabila, pt caSb↓, Sp↓, 25% rezultate fals+ (CDC)
HistopatologicReactie de amplificare genica
cercetare, beneficiu minim pt dg sitratamentul de rutina
30
Condiloame acuminate evolutie naturala
Pot spontan regresa, creste, ramaneneschimbateNetratate, 10-30% dispar spontan incca 3 luni
31
Condiloame acuminateprincipii de tratament
Nu exista o metoda terapeutica unica sisatisfacatoare in toate cazurileRatele de succes initiale sunt 50-75%cu majoritatea tratamentelorRecurentele sunt obisnuiteVaccinuri anti-PVU pot preveni infectia
32
Condiloame acuminatetratament
Metode aplicabile de catre pacientPodofilotoxina (Condyline) 3/7, 4-6 saptImiquimod (Aldara) 3/7, max 16 sapt
Metode aplicabile de personal medicalCrioterapiePodofilinaAcid tri-, bi-cloraceticCuretareElectrocauterizareFotovolatilizare laser
33
Vaccin anti-PVU (Gardasil)
Vaccinul este impotriva celor mai frecvente tulpinide PVU (6, 11, 16, 18)Este puternic imunogen - induce un raspuns imunfoarte intens, de 50 de ori mai mare decat raspunsulimun obtinut prin contactul natural cupapilomavirusul.Vaccinul nu are nici un risc din punct de vedere alinfectiozitatii sau riscului oncogenic, intrucat esteobtinut prin recombinare genica.Este in prezent autorizat si pentru vaccinareabaietilor (FDA 2010)
34
Vaccin anti-PVU - limitariLipsa datelor referitoare la durata raspunsului imunDate insuficiente referitoare la intensitatearaspunsului imun (titrul Ac este un marker surogat alraspunsului imun)Posibile infectii cu alte tipuri, deci screening-ultrebuie sa continueAcceptabilitatea sociala a vaccinuluiVaccinarea barbatilor (vaccinarea exclusiva afemeilor este cu 60-75% mai putin eficienta inprevenirea cancerului de col decat vaccinareaambelor sexe)
35
Tratamentrezultate asteptate
Scopul nu este eradicarea PVU (imposibila dincauza infectiei clinice subiacente)Tratarea leziunilor vizibile poate reduceinfectiozitatea si transmiterea (nedemonstrat)Tratamentul este exclusiv simptomatic si poatecontribui la cresterea perioadelor fara leziuniRecurentele sunt > 25% in primele 3 luniTratamentul este mai eficace pentrucondiloamele recente (< 1an)
36
Duct tape therapy for warts.Jerry Litt, 1978.
37
Tratamentul verucilor cu bandaadeziva (“duct tape”)
Metoda nedureroasa, lipsita de riscuri, ieftina sieficace pt verucile peri- si subunghiale
Tehnica:Infasurati complet veruca cu banda adezivapentru a realiza ocluzie completaLasati banda 6,5 zile, apoi faceti o pauza de12 ore; se repeta pana la disparitia veruciiDupa cateva sapt, veruca se micsoreaza, semacereaza si dispare
38
Don’t Excise - Exorcise.Duct tape therapy for warts.
Jerry Litt. Cutis 1978; 22: 673-76.
39
Ce este “duct tape”?
• Duct tape, or duck tape, is a polyethylene, reinforced,multi-purpose pressure sensitive tape with a soft andflexible shell and pressure sensitive adhesive. It isgenerally silver or black in color but many othercolors have recently become available. With astandard width of 1+7⁄8 inches (48 mm), duct tapewas originally developed during World War II in 1942as a water resistant sealing tape for ammunitioncases.
(http://en.wikipedia.org/wiki/Duct_tape)
40
41
Duct tape for the treatment of commonwarts in adults: a double-blind RCT
Arch Dermatol 2007• 90 immunocompetent adult volunteers with at least 1
wart measuring 2 to 15 mm enrolled. 80 completedthe study.
• There were no statistically significant differences inthe proportions of patients with resolution of thetarget wart (8 [21%] of 39 patients in the treatmentgroup vs 9 [22%] of 41 in the control group).
• Of patients with complete resolution, 6 (75%) in thetreatment group and 3 (33%) in the control group hadrecurrence of the target wart by the sixth month.
Arch Dermatol. 2007 Mar;143(3):309-13.
42
If the patient is you, try aplacebo or two.
43
Despre ce voi vorbi...
• Papilomavirusuri umane• Herpes simplex• Herpes zoster• Poxvirusuri• Pitiriazis rozat• Sarcom Kaposi• Manifestari cutanate in infectia HIV
44
Herpes simplex
Virus ADN - 2 tipuri antigenice (VHS1,VHS2)Produce infectie cronica, persistenta aggl nervilor senzitivi si recurentemucoase variabile si imprevizibile
45
Herpes simplex manifestari clinice
• A. Primo-infectia herpeticaF. inaparente (80-95% din infectiile VHS1)Gingivostomatita herpeticaHerpesul genital primarAlte forme:
Panaritiu herpeticKeratoconjunctivita
Forme graveEczema herpeticumHerpesul neonatalHerpesul la imunodeprimati
• B. Herpesul recurent
46
Herpes simplex - diagnostic
• Clinic - suficient pt cazurile tipice• Paraclinic
CitodiagnosticIFDCultura viralaSerologia - nu este utila pt dg. recurentelor
47
Herpes simplex - tratament
1.Antivirale care inhiba ADN-polimerazavirala dupa o fosforilare prealabilamediata de timidinkinaza (TK)herpetica (*ciclovir-uri)
2.Antivirale care inhiba ADN-polimerazavirala independent de timidinkinazaherpetica
48
Efectele tratamentului antiviral
Tratamentul recurentelor (intermitent)Scurteaza durata si severitate recurenteirespectiveNu influenteaza durata frecventa, duratasi severitatea recurentelor ulterioare
Tratamentul continuuReduce frecventa (cu >60-70%) siseveritatea recurentelor si ↓ eliminarileasimptomatice de virus
49
Indicatiile tratamentului antiviralcontinuu
Recurente frecvente (>6/an)Recurente complicateImunodeprimatiGravide la risc, dupa saptamana 36
50
Rezistenta la antivirale
Nu se dezvolta la persoaneimunocompetenteRisc mare de dezvoltare a rezistenteila imunodeprimatiMecanism: mutatii ale genei TK cudisparitia completa a genei →rezistenta incrucisata la *ciclovir-uri
51
Herpes simplex - tratament
AciclovirAnalog ciclic al guanozineiBiodisponibilitate 15%Trat recurentelor: 200 mg x 5/ziTrat continuu: 800 mg/zi in 1-2 prize
ValaciclovirEsterul L-valil al acicloviruluiBiodisponibilitate 54%Trat recurentelor: 500 mg x 2/ziTrat continuu: 500 mg/zi in 1-2 prize
52
Herpes simplex - tratament
FamciclovirTransformat in penciclovir (f. activa)Biodisponibilitate 77%Trat recurentelor: 250 mg x 3/ziTrat continuu: 125 mg x 2/zi
53
Herpes simplex - tratament
La persoanele cu rezistenta la antiviraleleclasice:Foscarnet
Nu se absoarbe oral, se adm i-vIndicat in infectiile cu VHS1,2 VVZ, CMV laimunodeprimati
CidofovirEficace topic si sistemic pe mutantii rezistenti laaciclovir si foscarnet
54
Despre ce voi vorbi...
• Papilomavirusuri umane• Herpes simplex• Herpes zoster• Poxvirusuri• Pitiriazis rozat• Sarcom Kaposi• Manifestari cutanate in infectia HIV
55
Herpes zoster
Reactivarea dermatomerica a virusuluivaricelo-zosterian → nu poate apareadecat la cei care au avut varicela
98% din adulti in decada 3 au Ac anti-VVZEruptia este unilaterala, formata dinvezicule grupate pe fond eritematos
56
Herpes zoster
VarstaIncidenta: < 1/1000 la copii vs. 12/1000 lapersoane > 65 ani
Factori de risc:↓ imunitatii la VVZ cu inaintarea in varstaImunosupresiaInfectia HIV
Varstnicii sunt mai expusi, deoarece odata cu inaintareain varsta are loc o reducere a imunitatii fata de virusul V-Z. De aceea, 66% dintre pacienti au peste 50ani
Mult mai rar, zosterul afecteaza si copii (5% dintre cei sub15 ani).
Alti factori de risc suntimunosupresia (mai ales cea indusa de bolilimfoproliferative si/sau tratmente chimioterapice)Infectia HIV (creste de 8 ori riscul de zoster).
57
Herpes zoster
Cele mai afectate teritorii:Ramurile trigemenuluiNervii intercostali
Complicatii:Forme severe hemoragice/necroticeVaricelizareSuprainfectie bacterianaAlgii post-zosteriene - cea mai frecventa
Varstnicii sunt mai expusi, deoarece odata cu inaintareain varsta are loc o reducere a imunitatii fata de virusul V-Z. De aceea, 66% dintre pacienti au peste 50ani
Mult mai rar, zosterul afecteaza si copii (5% dintre cei sub15 ani).
Alti factori de risc suntimunosupresia (mai ales cea indusa de bolilimfoproliferative si/sau tratmente chimioterapice)Infectia HIV (creste de 8 ori riscul de zoster).
58
59
60
Herpes zoster - tratament
Prevenire - prin imunizarea impotrivaVVZ sau prin vaccinarea adultilorVaccinarea persoanelor de >60 ani aredus:
Incidenta h. zoster cu 51.3%Incidenta algiilor postherpetice cu 66.5%Severitatea totala a h. zoster cu 61%
(NEJM 2005; 352: 2271-2284)
Exista vaccin cu virus viu atenuat (Varilrix, Varivax) - cu oeficienta de 80% in prevenirea infectiei simptomatice cuVVZ. 5% dintre copiii vaccinati fac rash. Vaccinul produceatat un raspuns mediat celular cat si unul umoral.
La adulti, care au venit deja in contact cu VVZ, vaccinul arputea fi util ca un rapel de reactivarea a imunitatii umoralesi celulare si ar putea contribui la reducerea incidenteiherpesului zoster.
A Vaccine to Prevent Herpes Zoster and PostherpeticNeuralgia in Older Adults (NEJM, June 2, 2005)
Background. The incidence and severity of herpes zosterand postherpetic neuralgia increase with age inassociation with a progressive decline in cell-mediatedimmunity to varicella–zoster virus (VZV). We tested thehypothesis that vaccination against VZV would decreasethe incidence, severity, or both of herpes zoster andpostherpetic neuralgia among older adults.
Methods. We enrolled 38,546 adults 60 years of age orolder in a randomized, double-blind, placebo-controlledtrial of an investigational live attenuated Oka/Merck VZVvaccine ("zoster vaccine"). Herpes zoster was diagnosedaccording to clinical and laboratory criteria. The pain anddiscomfort associated with herpes zoster were measuredrepeatedly for six months. The primary end point was theburden of illness due to herpes zoster, a measure affectedby the incidence, severity, and duration of the associatedpain and discomfort. The secondary end point was theincidence of postherpetic neuralgia.
Results. More than 95 percent of the subjects continued inthe study to its completion, with a median of 3.12 years ofsurveillance for herpes zoster. A total of 957 confirmedcases of herpes zoster (315 among vaccine recipientsand 642 among placebo recipients) and 107 cases ofpostherpetic neuralgia (27 among vaccine recipients and80 among placebo recipients) were included in theefficacy analysis. The use of the zoster vaccine reducedthe burden of illness due to herpes zoster by 61.1 percent(P<0.001), reduced the incidence of postherpeticneuralgia by 66.5 percent (P<0.001), and reduced theincidence of herpes zoster by 51.3 percent (P<0.001).Reactions at the injection site were more frequent amongvaccine recipients but were generally mild.
Conclusions. The zoster vaccine markedly reducedmorbidity from herpes zoster and postherpetic neuralgiaamong older adults.
61
62
Herpes zoster - tratament
Tratament etiologic:Aciclovir 800 mg x 5/zi, 7 zileValaciclovir/Famciclovir/Brivudin -
echivalente ca eficacitate cu aciclovirulcomplianta mai buna pt ca se administreazamai rarmai scumpe
Tratamentul algiilor
Exista vaccin cu virus viu atenuat (Varilrix, Varivax) - cu oeficienta de 80% in prevenirea infectiei simptomatice cuVVZ. 5% dintre copiii vaccinati fac rash. Vaccinul produceatat un raspuns mediat celular cat si unul umoral.
La adulti, care au venit deja in contact cu VVZ, vaccinul arputea fi util ca un rapel de reactivarea a imunitatii umoralesi celulare si ar putea contribui la reducerea incidenteiherpesului zoster.
A Vaccine to Prevent Herpes Zoster and PostherpeticNeuralgia in Older Adults (NEJM, June 2, 2005)
Background. The incidence and severity of herpes zosterand postherpetic neuralgia increase with age inassociation with a progressive decline in cell-mediatedimmunity to varicella–zoster virus (VZV). We tested thehypothesis that vaccination against VZV would decreasethe incidence, severity, or both of herpes zoster andpostherpetic neuralgia among older adults.
Methods. We enrolled 38,546 adults 60 years of age orolder in a randomized, double-blind, placebo-controlledtrial of an investigational live attenuated Oka/Merck VZVvaccine ("zoster vaccine"). Herpes zoster was diagnosedaccording to clinical and laboratory criteria. The pain anddiscomfort associated with herpes zoster were measuredrepeatedly for six months. The primary end point was theburden of illness due to herpes zoster, a measure affectedby the incidence, severity, and duration of the associatedpain and discomfort. The secondary end point was theincidence of postherpetic neuralgia.
Results. More than 95 percent of the subjects continued inthe study to its completion, with a median of 3.12 years ofsurveillance for herpes zoster. A total of 957 confirmedcases of herpes zoster (315 among vaccine recipientsand 642 among placebo recipients) and 107 cases ofpostherpetic neuralgia (27 among vaccine recipients and80 among placebo recipients) were included in theefficacy analysis. The use of the zoster vaccine reducedthe burden of illness due to herpes zoster by 61.1 percent(P<0.001), reduced the incidence of postherpeticneuralgia by 66.5 percent (P<0.001), and reduced theincidence of herpes zoster by 51.3 percent (P<0.001).Reactions at the injection site were more frequent amongvaccine recipients but were generally mild.
Conclusions. The zoster vaccine markedly reducedmorbidity from herpes zoster and postherpetic neuralgiaamong older adults.
63
The young physician starts life withtwenty drugs for each disease,
andthe old physician ends life withone drug for twenty diseases.
(W. Osler)
64
Despre ce voi vorbi...
• Papilomavirusuri umane• Herpes simplex• Herpes zoster• Poxvirusuri• Pitiriazis rozat• Sarcom Kaposi• Manifestari cutanate in infectia HIV
65
Pox-virusuri
Virusul ectimei contagiosum (orf)Virusul nodulilor mulgatorilorVirusul moluscumului contagiosum
66
Ectima contagiosumNodulii mulgatorilor
Produse de parapoxvirusuri ale carorgazde sunt:
Oile si caprele (ectima contagiosum)Bovinele (nodulii mulgatorilor)
Contaminarea umana are lor prininoculare directa de la animalelebolnave
67
Ectima contagiosumNodulii mulgatorilor
Manifestari clinice f. asemanatoarePapule rosii → noduli fermi, sensibili→ pustule/bule hemoragice, uneoriombilicate→ crustaLocalizare pe mainiFrecvent limfangita si adenopatiesatelitaSe vindeca spontan, fara cicatrice, in4-6 saptamani
68
(colectia dr. G. Turcu)
69
Molluscum contagiosum
Afectiune comuna, apare la oricevarsta, mai frecvent la copiiLa adult se localizeaza genital siperigenital (ITS)Transmiterea: hetero- si autoinoculare
70
Molluscum contagiosum
Manifestari:Papule de culoarea pielii, hemisferice, cucentrul ombilicatCresc lent si ating 5-10 mm in 6-12 saptPrin exprimarea continutului → “grauntiide molluscum”
71
72
73
74
Molluscum contagiosumtratament
CuretareCrioterapieExprimarea continutului + alcool iodatSol KOH 5%
75
Never underestimate thepower of body to heal
76
Despre ce voi vorbi...
• Papilomavirusuri umane• Herpes simplex• Herpes zoster• Poxvirusuri• Pitiriazis rozat• Sarcom Kaposi• Manifestari cutanate in infectia HIV
77
Pitiriazis rozat
• Robert Willan 1798• Camille Gibert 1860 (f. maculara)• Pierre Bazin 1862 (f. inelara, cea mai
frecventa)• Louis Brocq 1887 - placa heraldica
78
Epidemiologie
• Incidenta 0.39-4.80/100 pacienti dedermatologie
• 172/100.000 pers-ani in populatia generala• Majoritatea sunt tineri: 10-35 ani• Barbati-femei: 1:1.43• Variatii sezoniere ale frecventei• Agregari spatio-temporale ale cazurilor
79
Etiologie
Infectioasa (virala, HHV-7?)• Evolutie similara exantemelor virale• Absenta recidivelor• Asocierea cu infectii respiratorii• Gruparea spatio-temporala a cazurilor• Aparitia de PR dupa contact cu PR
Eruptiile pitiriazis rozat-like induse demedicamente sunt clasificate separat
80
Manifestari clinice
• Placa heraldica - 40-76%• Interval placa heraldica-eruptie: 2-84
zile (de obicei 7-14)• Eruptie eritemato-scuamoasa, ovalara,
cu descuamare “in coleret”, cu scuamemai aderente la periferia leziunii si maidetasate in centrul ei
81
82
Manifestari clinice
• Eruptia secunda: leziuni similara placiiheraldice, dar de dimensiuni mai mici
• Distributia leziunilor cu axul lung paralelcu liniile de tractiune ale pielii
• Localizata pe trunchi si radacinamembrelor
• Traditional respecta fata
83
84
85
86
Forme atipice
• Relativ frecvente• Forme: veziculoase, purpurice,
hemoragice, cu placi gigante, cu placifoarte mici, inversata (afect reg axilare,inghinale, fata)
• Afectarea cav orale - posibila
87
Chuh AA. JEADV 2003;17:101-3.
88
Tratament
• Nici un tratament• Eritromicina (sau alte macrolide)• Antivirale (aciclovir ? - eficacitate
redusa pe HHV-7)• Fototerapie (naturala, UVB)
89
Sarcomul Kaposi
• Tumora multifocala, indusa de infectia cuHHV-8, cu numeroase forme clinice
• Frecventa a crescut dupa aparitia HIV/SIDA• Riscul bolii la cei cu SIDA care au ca factor
de risc homosexualitatea este de 106.000 orimai mare decat in populatia generala, iar lacei cu alti factori de risc pentru SIDA de13.000 ori mai mare.
90
Sarcomul Kaposi - investigatii
• Biopsie (ptconfirmare)
• test HIV• investigatii uzuale• investigatii de
extensie (echo, CT)
91
Kaposi - forma clasica
• Barbat, >60 ani• Placi violacee• Debut mb inferioare• Hiperkeratoza• Pot dezvolta noduli• Pot ulcera
92
Forme de sarcom Kaposi
• Forma clasica (europeana) - la barbati varstnici,mai frecvent in zona mediteraneana, evol lenta &neagresiva; sex ratio B:F=15:1
• Forma endemica africana - la negri, are 4subtipuri (benigna nodulara, agresiva localizata,florida, limfadenopatica); sex ratio 1:1
• Forma epidemica (sidatica) - la pacienti cu SIDA,cea mai specifica manifestare in HIV/SIDA; sexratio B:F=3:1
• Forma iatrogenica (imunodeprimati) - sex ratio 1:1
93
Kaposi clasic vs. Kaposi sidatic
• pred barbati• de obicei > 60 ani• debut mb inferioare• leziuni putine• evolutie lenta• rareori afecteaza 1/2
superioara corp• nu afecteaza
mucoasele
• pred la homosexuali• in faza de SIDA• fara zone electie• leziui numeroase• evolutie rapida• afect extracutanata
precoce• afect mucoasa
frecventa• Kobnerizare
94
Diagnostic diferential
• Angiom• Granulom piogenic• Angiokeratom• Insuficienta venoasa severa (pseudo-Kaposi)• Sindromul Blue Rubber Bleb Nevus• Nevi• Dermatofibrom
95
96
Evolutie
• Variabila - de la afectare exclusivcutanata la afectare cutanata siextracutanata rapid progresiva.
• Influentata de forma de boala si deteren.
97
Tratament
• Conservator (watchful waiting)• Excizia/cauterizarea ariilor sever afectate• Radioterapie• Antivirale (foscarnet, HAART)• Chimioterapie intralezionala (eg vincristina) sau
sistemica (vinblastina, paclitaxel, docetaxel)• Intreruperea imunosupresoarelor la cei
imunosupresati iatrogen
98
The therapist walks a tight ropebetween faith and skepticism,
but should he fall, let if betoward faith.
99
Manifestari cutanate in HIV/SIDA
• Neoplazice: Kaposi, limfoame, epitelioame• Infectioase:
– virale (herpes extins, zoster necrotic, HPV, molluscum)– bacteriene (angiomatoza bacilara, mycobacterioze atipice,
sifilis)– fungice (candidoze, criptococoza, coccidioidomicoza)– ectoparazitare (scabie norvegiana)– parazitare (pneumocistoza extrapulmonara, toxoplasmoza)
• Neclasificabile: d. seboreica, eruptii papuloase, afectautoimune, reactii postmedicamentoase
Recommended